PSYCHOLOGICAL EFFECTS OF OVARIAN CANCER OFTEN OVERLOOKED, BUT CAN HAVE A SIGNIFICANT IMPACT ON PATIENTS – NEW EUROPEAN LITERATURE REVIEW REVEALS

79% of patients felt uncomfortable raising psychological and emotional concerns during their consultations1 Disease recurrence is of greatest concern for ovarian cancer patients, but poorly addressed, with 53% of patients saying symptoms of recurrence have not been discussed with them2

TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®

Results demonstrate ZEJULA activity beyond patients with BRCA mutations in late-line ovarian cancer treatment setting QUADRA data accepted for presentation at 2018 ASCO annual meeting Data intended to support label expansion with biomarker in the treatment setting WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) — TESARO, Inc.(NASDAQ:TSRO),

TESARO Summarizes TSR-042 Clinical Data Presented at AACR

Activity of TSR-042 (anti-PD-1 antibody) monotherapy demonstrated in patients with MSI-high endometrial and non-small cell lung cancers Data support unique and convenient dosing schedule Regulatory submission for TSR-042 for MSI-high tumors planned in 2H 2019 CHICAGO, April 16, 2018 (GLOBE NEWSWIRE) — TESARO,